Abstract: A method for depth mapping includes receiving optical radiation reflected from multiple points on an object and processing the received optical radiation to generate depth data including multiple candidate depth coordinates for each of a plurality of pixels and respective measures of confidence associated with the candidate depth coordinates. One of the candidate depth coordinates is selected at each of the plurality of the pixels responsively to the respective measures of confidence. A depth map of the object is output, including the selected one of the candidate depth coordinates at each of the plurality of the pixels.

Abstract: The present invention relates to combinations and methods based on Baclofen and Acamprosate for the treatment of Alzheimer's disease or Alzheimer's related disorders in patients who do not respond to an inhibitor of acetylcholinesterase, typically in patients treated with an inhibitor of acetylcholinesterase and who have lost responsiveness to said inhibitor of acetylcholinesterase.

Abstract: Systems and methods disclosed herein relate to assigning dynamic eye-gaze dwell-times. Dynamic dwell-times may be tailored to the individual user. For example, a dynamic dwell-time system may be configured to receive data from the user, such as the duration of time the user takes to execute certain actions within applications (e.g., read a word suggestion before actually selecting it). The dynamic dwell-time system may also prevent users from making unintended selections by providing different dwell times for different buttons. Specifically, on a user interface, longer dwell times may be established for the critical keys (e.g., “close” program key, “send” key, word suggestions, and the like) and shorter dwell times may be established for the less critical keys (e.g., individual character keys on a virtual keyboard, spacebar, backspace, and the like).

Abstract: Systems and methods for enabling communications via tablature for an application are disclosed. A system may include at least one processor configured to generate a table containing cells for holding values and enable association of a communications rule with a specific cell of the table, wherein the communications rule includes a trigger that automatically activates when a specific value in the specific cell meets a criterion. The processor may trigger the communications rule when the specific value in the specific cell meets the criterion, and communicate, upon triggering of the communications rule, a message relating to the specific value in the specific cell meeting the criterion.

Abstract: A novel method for measurement of velocity and diffusion constant in microfluidic channels is presented using nano-NMR techniques. The fluid molecules of interest interact with color centers implanted in a suitable substrate such as diamond. A magnetic dipolar interaction between the fluid molecule spins influences the state of the NV, which can be probed using known NMR techniques. The color center response is read out optically and the NMR spectrum can be reconstructed from this optical information. The noise in the NMR spectra can be analyzed (e.g. in terms of its correlation function) to directly yield measurements of velocity and diffusion constant in the fluid, at orders of magnitude greater accuracy than otherwise possible.

Abstract: The present invention relates to compositions and methods for the treatment of epilepsy and related disorders. More specifically, the present invention relates to novel combinatorial therapies of epilepsy and related disorders.

Abstract: The present invention provides methods for treating, preventing, or delaying the onset of Charcot-Marie-Tooth Disease type 1A (CMT1A), by administering to a subject in need thereof a combination comprising baclofen, sorbitol and naltrexone, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to combinations and methods for the treatment of neurological disorders related to amyloid beta toxicity and/or neuronal death and/or glucose-impaired neuronal metabolism. More specifically, the present invention relates to novel combinatorial therapies of Alzheimer's disease, Alzheimer's disease-related disorders, frontotemporal dementia, Parkinson's disease, Lewy body dementia, Huntington's disease, peripheral neuropathies, alcoholism or alcohol withdrawal, neurological manifestations of drug abuse or drug abuse withdrawal, amyotrophic lateral sclerosis, multiple sclerosis, spinal cord injury, epilepsy, traumatic brain injury or brain ischemic events based on baclofen, acamprosate and at least one medium chain triglyceride.

Abstract: The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related disorders.

Abstract: Compositions and methods for the treatment of Alzheimer's disease and related disorders. More particularly, disclosed are combined therapies that modulate synapse function for treating the disease.

Abstract: The present invention relates to a homogeneous, stable, and palatable pharmaceutical solution comprising baclofen, sorbitol and naltrexone.

Abstract: Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either R1 or R2 is independently selected from Cl, F, —CF3, or —CH3, and the other is hydrogen, and methods for their use are provided.

Abstract: The present invention relates to combinations and methods for the treatment of neurological disorders related Amyloid beta toxicity and/or neuronal death. More specifically, the present invention relates to novel combinatorial therapies of Alzheimer's disease, Alzheimer's disease related disorders, Parkinson's disease, Lewy body dementia, multiple system atrophy and other related synucleinopathies, Huntington's disease, peripheral neuropathies, alcoholism or alcohol withdrawal, neurological manifestations of drug abuse or drug abuse withdrawal, amyotrophic lateral sclerosis, multiple sclerosis, spinal cord injury, epilepsy, traumatic brain injury or brain ischemic events based on 3-phenylsulfonyl-8-(piperazin-1-yl) quinoline and baclofen and/or acamprosate.

Abstract: The present invention relates to methods for improving dose finding process for combinations of several drugs and/or adapting the dosage of combinatorial treatment. More particularly the invention relates to methods for identifying more efficient dose of active pharmaceutical ingredients (APIs) within combination therapies. This invention also relates to methods for optimizing a therapeutic efficiency of combined therapies.

Abstract: A mobile unit comprising a processing resource configured to: (a) connect, via a network interface, to a first organizational network of the organizational networks, the first organizational network being an active organizational network; (b) obtain network traffic comprising a plurality of first packets originating from at least one of the active organizational network's IT systems and a plurality of second packets originating from at least one of the active organizational network's OT systems; (c) perform Deep Packet Inspection (DPI) of the second packets, for obtaining DPI information; (d) record, on a media, the first packets and the DPI information; (e) disconnect from the active organizational network; (f) connect, via the network interface, to a subsequent organizational network of the organizational networks, the subsequent organizational network being the active organizational network after connecting thereto; and (g) repeat steps (b) to (f).

Abstract: The present invention relates to certain novel 2,3-dihydro-1H-indole compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioblastoma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma.

Abstract: The present invention relates to combinatorial therapies and methods for the treatment of Alzheimer's disease or an Alzheimer's disease related disorder based on idalopirdine, baclofen and acamprosate, wherein idalopirdine is provided as suboptimal doses.

Abstract: The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related disorders.

Abstract: The present invention relates to compositions and methods for controlling glycaemia in a mammalian in need thereof. The present invention relates to compositions and methods for the treatment of diabetes disease and related disorders. More specifically, the present invention relates to novel therapies or combinatorial therapies of diabetes and related disorders, based on compositions controlling the blood glucose level.